RxDoctor Payments Data

Sylvia Riedler, MD

Internal Medicine · Virginia Beach, VANPI 1952405680

Payments from drug & device makers

$1,709in general payments, 2019–2025

Across 102 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$291
  • Sanofi-aventis U.S. LLC$221
  • Lilly USA, LLC$188
  • Avanir Pharmaceuticals, Inc.$169
  • Pfizer$152
  • Amgen$120
  • plus $570 from 13 others

What the payments were for

  • Food & beverage$1,703100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,709 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$119,727
Medicare patients
370
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$89,433
JardianceEmpagliflozin26$41,926
OzempicSemaglutide22$29,988
FarxigaDapagliflozin Propanediol26$26,238
XareltoRivaroxaban13$11,668
SymbicortBudesonide/Formoterol Fumarate12$4,028
SynthroidLevothyroxine Sodium63$3,656
Losartan Potassium229$2,837
Atorvastatin Calcium310$2,592
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,210
Rosuvastatin Calcium168$2,181
Metoprolol Succinate136$1,931
Omeprazole160$1,854
Amlodipine Besylate222$1,471
Levothyroxine Sodium151$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$89,43369 claims
Boehringer IngelheimJardiance$75$41,92626 claims
AstraZenecaFarxiga, Symbicort$291$30,26638 claims
Novo NordiskOzempic$79$29,98822 claims
AbbVieSynthroid$44$3,65663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →